CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Magnetic Esophageal Sphincter Augmentation to Treat Gastroesophageal Reflux

Policy governing coverage determination for laparoscopic magnetic esophageal sphincter augmentation (MSA/LINX) insertion to treat gastroesophageal reflux disease for Blue Cross Blue Shield - Rhode Island commercial and Medicare Advantage products. The policy addresses coverage stance, applicable CPT code, and references related policies and evidence; it applies to the insertion procedure only (removal covered under a related policy).

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMagnetic Esophageal Sphincter Augmentation to Treat Gastroesophageal Reflux

Policy CodePolicy N/A

Change TypeClarified insertion-only scope

Effective DateJan 1, 2017

Next Review Date

Key ActionClaims billed with CPT 43284 for insertion are not covered/not medically necessary; consult benefit documents for member-specific coverage and refer to the related policy for device removal.

POLICY UPDATE CHANGES

Policy states that insertion only is addressed and removal is covered under a related policy.

1Procedure codes explicitly not covered

2Payer populations addressed

2012-2024FDA/regulatory timeframe cited

Coverage Summary

This policy governs coverage determinations for laparoscopic magnetic esophageal sphincter augmentation (MSA/LINX) insertion for gastroesophageal reflux disease for Blue Cross Blue Shield - Rhode Island Medicare Advantage and Commercial products. The policy explicitly applies to the insertion only; removal of implanted devices is addressed in a related policy on Removal of Implantable Devices.

For Medicare Advantage members, magnetic esophageal sphincter augmentation to treat GERD is not covered because the evidence is insufficient to determine the effects of the technology on health outcomes. For Commercial products, MSA insertion is considered not medically necessary for the same reason. The policy lists CPT 43284 as a procedure code that is not covered / not medically necessary for these populations.

Medical Necessity / Coverage Determinations

Coverage Determination

Policy statements for Medicare Advantage Plans and Commercial Products:

Medicare Advantage Plans: Magnetic esophageal sphincter augmentation to treat gastroesophageal reflux disease is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes
Commercial Products: Magnetic esophageal sphincter augmentation to treat gastroesophageal reflux disease is not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes
Insertion vs Removal: Policy applies to insertion only; removal of devices referenced to related policy 'Removal of Implantable Devices'

Provider Actions & Billing Impact

Denial Risk

Claims for MSA insertion will be denied/not covered

Claims billed with CPT 43284 for magnetic esophageal sphincter augmentation insertion are not covered for Medicare Advantage and are not medically necessary for Commercial Products; providers should not expect payment and should consult member benefit documents for member-specific coverage.

Affected code: 43284
Consult the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for member-specific coverage and benefits

Documentation Required

Refer to related policy for device removal

This policy addresses insertion of the magnetic esophageal sphincter augmentation device only. Removal of implanted devices is addressed under the related policy 'Removal of Implantable Devices.' Document device removal per that related policy.

Document device removal using the guidance in the 'Removal of Implantable Devices' related policy

Background & Evidence Summary

The LINX Reflux Management System is a laparoscopically implanted ring of 10–18 interlinked titanium beads with magnetic cores placed around the gastroesophageal junction to augment the lower esophageal sphincter for patients with GERD inadequately controlled with medical therapy. The device received FDA premarket approval in 2012.

Regulatory history includes a manufacturer-initiated device recall in 2018 for possible separation of the bead component from the wire link; that recall was terminated on November 4, 2020. In March 2018 the FDA updated precautions related to hiatal hernia repair at the time of implantation. In February 2024 the FDA revised labeling removing a precautionary statement about Barrett's esophagus but adding guidance that LINX has not been proven to treat Barrett's Esophagus or prevent progression to cancer and that patients with BE should discuss ongoing BE management (which may include continuing PPIs) with their physicians.

The policy conclusion is that the evidence is insufficient to demonstrate an improvement in net health outcome compared with alternatives (including medical therapy and fundoplication). Consequently, insertion of MSA/LINX is not covered for Medicare Advantage and is not medically necessary for Commercial Products (see related policy for removal of devices).

Definitions

Unsupported block type: definition

Unsupported block type: note

Unsupported block type: code

Revision History

2017-01-01effective

Policy effective date: Medical Coverage Policy for Magnetic Esophageal Sphincter Augmentation to Treat Gastroesophageal Reflux became effective.

2026-01-07reviewedLatest

Policy last reviewed on this date.

clarified

Language clarified insertion-only scope; removal directed to related policy (Removal of Implantable Devices).